-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Refuge Biotechnologies, Inc.
, a shareholding company of 3SBio, and the University of Texas MD Anderson Cancer Center announced a strategic cooperation to develop new smart cells for the treatment of solid tumors
.
This cooperation combines Refuge's innovative technology with MD Anderson's biologics development platform experience and industrial strength
According to this collaboration, MD Anderson has the exclusive right to apply Refuge's proprietary next-generation cell engineering platform to its tumor infiltrating lymphocyte project
.
MD Anderson will also jointly develop Refuge's RB-340 and participate in clinical new drug (IND) declaration, GMP production and phase I/II clinical trials
Previously, in 2018, China's leading biopharmaceutical company 3SBio, Sequoia China, and Series A investors completed a US$25 million Series B investment in Refuge, and announced the cooperation with Refuge to jointly develop smart cells and enjoy certain designated products in China Priority for commercialization
.
Dr.
Bing Wang, CEO and co-founder of Refuge, said: “MD Anderson has extensive expertise in the development and manufacturing of innovative smart cells, such as groundbreaking research on TIL
.
We look forward to working closely with MD Anderson researchers.
Dr.
Jason Bock, MD Anderson's Vice President of Therapeutics Discovery and Head of Biologics Development, said: "I believe that TIL will have a significant impact in the field of cancer treatment, and improving the engineering design of TIL is an important part of driving this change
.
Under Refuge We are deeply encouraged by the application data of a generation of environment-related induced cell engineering platform, and we look forward to incorporating its potential into our TIL project
Dr.
Jing Lou, Chairman of 3SBio, said: “3SBio has always been committed to exploring cutting-edge innovative therapies
.
The cooperation with Refuge shows that we are determined to develop cutting-edge genetic engineering technologies to treat cancer and other diseases for which medical needs are not met.
